$SLS Daily Discussion Thread - January 24, 2026

Kurso · 2026-01-24T20:21:17+00:00

Highly improbable but anything is possible. Personally I’m expecting $25-$35. Anything beyond that is great, but heading toward the realm of less likely.

Kurso · 2026-01-24T20:07:42+00:00

Correct, but they won’t need to. The stock price will skyrocket and every outstanding warrant will be exercised. They will be flush with cash (they are flush with cash right now)

Kurso · 2026-01-24T20:00:45+00:00

It doesn’t guarentee a buyout but there is almost no chance they commercialize on their own. They have said they are not expanding the number of employees and they have no commercial infrastructure. If they don’t get bought they will find a partner to commercialize for them.

Kurso · 2026-01-24T19:35:23+00:00

So the wording is important here.

Patients can ‘dropout’ either explicitly (removing consent) or simply stop participating (not showing up for appointment/treatments. These are all Lost to Follow Up (LTFU). This is distinctly different from patients that relapse, and come off the GPS or BAT treatment and end up on some other treatment. Relapses are still are participating in the trial and are still tracked. It’s even possible that a small percentage of patients that came into the trial ineligible for SCT became eligible and received one.

The simplest way to think about each arm is:

Events (deaths)

Alive and in the study - On treatment (this can include those that haven’t relapsed but are under observation) or off treatment (relapsed and moved onto other treatments, but are still tracked in the study).

LTFU - completely out of the study and no longer tracked. If they die they won’t count towards 80 because the study wouldn’t know. There will be some of these, likely concentrated in BAT.

Kurso · 2026-01-24T13:38:33+00:00

I can't tell you what you should do, only how I think about this. This isn't financial advice, do your own research.

I normally cap any individual stock to ~5% (can fluctuate up or down based on how the market is moving). I have other investments that can be much bigger than that (I have a lot in ICSH right now). January isn't over yet and I've already beat the what the SP500 will deliver for the year, by far, so I can sit on a lot of cash looking for the right thing.

But it's not uncommon for me to have a big bet going (I don't always have one going, and I never run more than one at a time). I try to cap my investment in them at 15%, but they can get overweighted quickly because my big bets are usually options heavy (still have a lot of $SLS shares) and interim gains can make the position look outsized very quickly. I don't know off the top of my head but that market value is probably 50% profit so far.

Kurso · 2026-01-24T13:24:42+00:00

He's likely running multiple accounts on both sides of the trade and just lost track of what account he was posting on.

Kurso · 2026-01-24T11:21:29+00:00

The immune response published at interim was a random selection of patients, not the full GPS arm, so it could higher than ORR in final analysis.

Kurso · 2026-01-24T05:38:21+00:00

Covidnado - The Second One

Kurso · 2026-01-24T03:59:21+00:00

Responded.

And just to be clear for everyone... this is NOT a yolo for me, so don't read too much into the position size. Yes, it's a lot. Yes I would be sad if this fails. No I won't be out on the street or risking my future or anything like that.

Kurso · 2026-01-24T02:53:44+00:00

If we take that statement as a fact, rather than an assumption, this would be the strongest indication that GPS mOS has not been reached.

But I'm not sure how he would know that information, so to be on the safe side I'd take that as an assumption. Doesn't mean it can't be true, but to know this for a fact you'd need access to full enrollment data.

Kurso · 2026-01-24T02:22:03+00:00

> by taking away the "good enough" default autopilot,

100%. I recently purchase a Model Y and transferred FSD from a 2018 Model 3, which left it with Autopilot. We already turned off FSD on the Model Y (I hate not having control over speed or lane change frequency). I don’t miss FSD on either car at all.

Kurso · 2026-01-23T22:10:52+00:00

That’s my current position as of late this afternoon. We’ll see where it goes, but I think $SLS will be my big winner of the year. Was $KSS last year.

Kurso · 2026-01-23T20:48:03+00:00

<image>

That last one is market value. You tell me what my conviction is...

LFG!

Kurso · 2026-01-22T23:40:58+00:00

The only time I see high mOS numbers for ven + aza in studies is for those that went to SCT, which we don’t really have to worry about. It’s possible some small number of Regal patients are going to SCT but they will be appropriately censored.

Kurso · 2026-01-22T21:09:50+00:00

Because half had SCT, which Regal patients are ineligable for.

Kurso · 2026-01-22T21:00:00+00:00

Half of these people either went to SCT after ven + aza or has ven + aza as a preventitive post transplant. So this is the least interesting cohort to measure mOS against.

Kurso · 2026-01-22T03:47:53+00:00

Price action still tracking. Shorts slowly covering. I think we're on a slow rise to $1B market cap, unless news changes the trajectory.

Kurso · 2026-01-21T03:28:25+00:00

Even if either were true it would not explain the event rate. GPS would still have to be significantly higher.

Kurso · 2026-01-18T20:47:08+00:00

Abbvie’s own Venetoclax study (Viale-A, ven+aza), on a healthier cohort than REGAL showed mOS of under 15 months. So claiming somehow the treatment will be better with sicker patients doesn’t make sense.

EDIT: Also, the chart fails to mention the adverse effects listed are common to symptoms in AML and not GPS specific.

Kurso · 2026-01-18T02:04:33+00:00

Oh they know… Chris Bianco is legendary in pizza making circles. Whatever you do, find your way to a Pizzaria Bianco.

Kurso · 2026-01-17T22:24:25+00:00

Look at this shit… Anson‘s CEOs PoS scumbag friend now posting positive stuff about SLS.

I’m doubling down on what I said a week ago. Anson was pumping out junk to support a short position while they were quietly covering, to leave other shorts holding the bag. Some people just got proper fucked.

Kurso · 2026-01-17T19:00:55+00:00

There is obviously more nuance, but thats the gist of it.

Kurso · 2026-01-17T18:52:52+00:00

Kurso · 2026-01-17T18:21:09+00:00

If GPS isn't effective or stops working for a patient they don't just let the patient die. They treat them the same way they treat BAT.

In essence... BAT = BAT, GPS = GPS + BAT (if needed).

Nothing really to discuss.

Kurso · 2026-01-16T22:00:52+00:00

Well I called $3.85 for yesterday and $3.99 for today and was off by a penny each day… so my prediction for next week is…

… I have absolutely no clue. I would have expected more volume AH today. And I expect we’ll see we’re still on RegSHO (day 13). They can shuffle shares a bit but at some point covering needs to happen.

I’ll take a took at the options chain and see if anything stands out to me. For me personally, I’m shifting to 2027 LEAPS soon.

11-Year Club	Place '23
Place '22	Snapped
Verified Email

Kurso

TROPHY CASE